ACHC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Not a good buy right now for an impatient investor: the broader trend is still bearish (SMA200 > SMA20 > SMA5) and the stock is trading below the key pivot (14.251), suggesting rallies may fade.", "Sentiment backdrop is weak: multiple downgrades/price-target cuts since early Dec, plus hedge funds have been selling aggressively (+194.77% QoQ selling increase).", "A near-term bounce is possible only as a tactical trade if price holds the S1 support (~13.163), but the setup lacks a strong trigger and options imply elevated uncertainty into the next earnings (2026-02-26).", "Intellectia Proprietary Trading Signals: - AI Stock Picker: no signal on given stock today. - SwingMax: No signal on given stock recently."]
["Trend/MAs: Bearish structure with SMA200 > SMA20 > SMA5, indicating the stock remains in a broader downtrend despite the recent daily pop.", "Momentum: MACD histogram is positive and expanding (0.0575), hinting at improving short-term momentum, but it has not yet flipped the longer trend.", "RSI: RSI(6) ~50.9 (neutral), confirming lack of strong upside momentum confirmation.", "Levels: Support S1 ~13.163 then S2 ~12.49; resistance at Pivot 14.251 then R1 ~15.34. At 13.45, price is closer to support than resistance, but still below pivot (bearish control).", "Pattern-based odds (provided): ~70% chance of a small gain next day (+2.78%) and next week (+3.13%), but slightly negative over the next month (-0.51%)\u2014fits a short-lived bounce risk within a larger downtrend."]
with improving MACD momentum.", "If professional/general liability (PLGL) costs stabilize, the stock could re-rate given how compressed sentiment has become (some analysts still rate it Buy/Outperform despite cuts).", "Upcoming earnings (QDEC 2025 on 2026-02-26 after hours) can reset expectations if guidance/PLGL commentary improves."]
["Analyst narrative centers on repeated guidance cuts and elevated liability/legal expenses\u2014limited near-term catalysts cited by Jefferies and others.", "Hedge funds are selling aggressively (selling amount +194.77% over last quarter), a notable sentiment/positioning headwind.", "Price is below pivot and long-term moving averages remain bearishly stacked\u2014technicals still favor sellers on strength.", "No supportive news flow in the last week (no fresh positive catalyst), while the next major catalyst is earnings (binary risk with elevated IV)."]
["Latest quarter: 2025/Q3.", "Growth: Revenue increased to $851.6M (+4.41% YoY), indicating the top line is still growing modestly.", "Profitability: Net income fell to $36.2M (-46.8% YoY) and EPS fell to $0.40 (-45.95% YoY), showing significant earnings compression (consistent with liability/legal expense overhang referenced by analysts).", "Bottom line: Revenue growth is intact, but earnings deterioration is the key issue\u2014until profitability stabilizes, it\u2019s hard to justify buying aggressively into a downtrend."]
["Recent trend is decisively negative: a wave of price target cuts and multiple downgrades since early Dec, capped by Jefferies (2026-01-22) downgrade to Hold with PT slashed to $15 from $34.", "Key bearish points from Wall Street: recurring guidance reductions, unexpected PLGL/legal expense increases, limited near-term catalysts, and expectation the stock stays range-bound until sustained same-facility improvement and margin expansion appear.", "Key bullish/constructive points: some firms still maintain Buy/Outperform ratings (e.g., TD Cowen, UBS, RBC, Deutsche Bank) arguing for upside if cost headwinds normalize, but their lowered targets show reduced conviction and longer timelines."]
